USCOM LIMITED — Regulatory Filings 2017

Nov 20, 2017

ASX MEDIA RELEASE

International Hypertension Study Recommends Uscom BP+ Measures

• Journal American Heart Association published hypertension study

• Uscom BP+ central BP identified treatment benefits not identified by conventional arm BP

• Recommendation – “future trials should include measuring central BP parameters (BP+) ….. rather than rely solely on brachial BP.”

SYDNEY, Australia, Tuesday 21[st] November 2017: Uscom Limited (ASX code: UCM) (the Company or Uscom ) announced the publication of new research in the Journal of the American Heart Association from authors at the Uni of Auckland (Auckland), Imperial College (London), Uni Cambridge (Cambridge), University College (London), Mass General/Harvard (Boston), the Austrian Institute of Technology (Vienna) and the Uni of Otago (Christchurch) and recommended the use of Uscom BP+ measured central BP as routine for future BP trials. The multi-centre, double blinded, randomised, placebo controlled hypertension study found that Uscom BP+ identified significant changes in central BP during treatment for hypertension, while a leading conventional arm based BP method (Omron) did not.

The study of 517 adults demonstrated that patients with Vitamin D deficiency had their Uscom BP+ central BP measures improved with Vit D treatment, while no changes in brachial (arm) pressures were detected by the Omron device in the same patients.

The Uscom BP+ suprasystolic oscillometric method is patent protected in many international jurisdictions and is currently being rolled out as regional regulatory approvals permit. Revenue is beginning and is expected to accelerate throughout 2018.

Executive Chairman of Uscom, Associate Professor Rob Phillips said “This is exciting new evidence from some of the most influential academics in the global hypertension field, indicating the Uscom BP+ is more effective for detecting the BP changes associated with treatment benefits than a conventional device from the current leading manufacturer. The authors also recommended the routine adoption of Uscom BP+ central BP measures in future hypertension trials. The BP+ is patent protected, practice leading technology, and while it has been implemented on the International Space Station for a number of years as a research device, this is the first major study demonstrating the BP+ superiority to conventional BP monitors and to recommend it for routine global application. These data suggest that hypertensive patients using conventional arm based BP home monitors may benefit from changing to Uscom BP+ monitoring of their central BP.”

The global hypertension device market is reported to be in the order of $5B USD, while $74B PA is reportedly spent on management of hypertension and hypertension complications in the US alone. So the scale of the Uscom BP+ opportunity is both substantial and uncertain. Omron, the current market leader in the BP space, and the technology against which the BP+ was compared has a $1.4B AUD annual Healthcare revenue. While Uscom plans to retain the BP+ technology as a foundation for accelerated revenue growth over the next decade, it could also be strategically licensed or on sold into international distributors.

Reference: Sluyter JD, Camargo, CA, Stewart AW, Waayer D, Lawes CMM, Toop L, Khaw KT, Thom SAM, Hametner B, Wassertheurer S, Parker KH, Hughes AD, Scragg R. Effect of Monthly, High-Dose, Long-Term Vitamin D Supplementation on Central Blood Pressure Parameters: A Randomized Controlled Trial Substudy. J Am Heart Assoc. 2017;6:e006802. DOI: 10.1161/JAHA.117.006802.

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A : A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote telemonitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary SpiroReporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse spirometry outputs and generate summary reports.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au

Brett Crowley Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au